Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity

Cancer Immunology, Immunotherapy

Volumn 63, Issue 5, 2014, Pages 501-511

  Rigo, Valentina ^a,c   Corrias, Maria Valeria ^b   Orengo, Anna Maria ^a   Brizzolara, Antonella ^a   Emionite, Laura ^a   Fenoglio, Daniela ^a,c,d   Filaci, Gilberto ^a,c,d   Croce, Michela ^a   Ferrini, Silvano ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

IL 21; Immunotherapy; Monoclonal antibody; Neuroblastoma; T cells

Indexed keywords

CD4 ANTIBODY; INTERLEUKIN 21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENTIATION; FEMALE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CANCER VACCINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOTHERAPY; INTERLEUKINS; LYMPHOCYTE DEPLETION; MICE; NEUROBLASTOMA; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 84899930333     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1536-9     Document Type: Article

References (46)

1. Haupt R, Garaventa A, Gambini C et al (2010) Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian neuroblastoma registry. J Clin Oncol 28:2331-2338. doi: 10.1200/JCO.2009.24.8351
2. Cohn SL, Pearson AD, London WB et al (2009) The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol 27:298-303. doi: 10.1200/JCO.2008.16.6876
3. Garaventa A, Parodi S, De Bernardi B et al (2009) Outcome of children with neuroblastoma after progression or relapse: a retrospective study of the Italian neuroblastoma registry. Eur J Cancer 45:2835-2842. doi: 10.1016/j.ejca.2009.06.010
4. London WB, Castel V, Monclair T et al (2011) Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol 29:3286-3292. doi: 10.1200/JCO.2010.34.3392
5. Seeger RC (2011) Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 21:229-237. doi: 10.1016/j
6. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA (1998) Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91:1706-1715
7. Corrias MV, Basso S, Meazza R, Musiani P, Santi L, Bocca P, Occhino M, Ferrini S, Pistoia V (1998) Characterization and tumorigenicity of human neuroblastoma cells transfected with the IL-2 gene. Cancer Gene Ther 5:38-44
8. Ladenstein R, Pötschger U, Siabalis D et al (2011) Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after mega therapy and autologous stem-cell reinfusion. J Clin Oncol 29:441-448. doi: 10.1200/JCO.2009.23.5465
9. Coventry BJ, Ashdown ML (2012) The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manag Res 4:215-221. doi: 10.2147/CMAR.S33979
10. Liao W, Lin JX, Leonard WJ (2013) Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38:13-25. doi: 10.1016/j.immuni.2013.01.004
11. Bayer AL, Yu A, Adeegbe D, Malek TR (2005) Essential role for interleukin-2 for CD4(+) CD25(+) T regulatory cell development during the neonatal period. J Exp Med 201:769-777
12. Rochman Y, Spolski R, Leonard WJ (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9:480-490. doi: 10.1038/nri2580
13. Comes A, Rosso O, Orengo AM et al (2006) CD25+ regulatory T cell depletion augments immunotherapy of micrometastasis by an IL-21-secreting cellular vaccine. J Immunol 176:1750-1758
14. Peluso I, Fantini MC, Fina D, Caruso R, Boirivant M, Macdonald TT, Pallone F, Monteleone G (2007) IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 178:732-739
15. Parrish-Novak J, Dillon SR, Nelson A et al (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57-63
16. Albrecht J, Frey M, Teschner D, Carbol A, Theobald M, Herr W, Distler E (2011) IL-21-treated naive CD45RA+ CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype. Cancer Immunol Immunother 60:235-248. doi: 10.1007/s00262-010-0936-8
17. Wölfl M, Merker K, Morbach H, Van Gool SW, Eyrich M, Greenberg PD, Schlegel PG (2011) Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. Cancer Immunol Immunother 60:173-186. doi: 10.1007/s00262-010-0928-8
18. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA (2004) IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 173:900-909
19. Sutherland AP, Joller N, Michaud M, Liu SM, Kuchroo VK, Grusby MJ (2013) IL-21 promotes CD8+ CTL activity via the transcription factor T-bet. J Immunol 190:3977-3984. doi: 10.4049/jimmunol.1201730
20. Di Carlo E, de Totero D, Piazza T, Fabbi M, Ferrini S (2007) Role of IL-21 in immune-regulation and tumor immunotherapy. Cancer Immunol Immunother 56:1323-1334
21. Andorsky DJ, Timmerman JM (2008) Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther 8:1295-1307. doi: 10.1517/14712598.8.9. 1295
22. Croce M, Meazza R, Orengo AM et al (2008) Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 57:1625-1634. doi: 10.1007/s00262-008-0496-3
23. Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, Musiani P, Colombo MP, Ferrini S (2004) IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J Immunol 172:1540-1547
24. Daga A, Orengo AM, Gangemi RM, Marubbi D, Perera M, Comes A, Ferrini S, Corte G (2007) Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer 121:1756-1763
25. Kowalczyk A, Wierzbicki A, Gil M et al (2007) Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Cancer Immunol Immunother 56:1443-1458
26. Dodds MG, Frederiksen KS, Skak K, Hansen LT, Lundsgaard D, Thompson JA, Hughes SD (2009) Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunol Immunother 58:843-854. doi: 10.1007/s00262-008-0600-8
27. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF (2008) Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 26:2034-2039. doi: 10.1200/JCO.2007.14.5193
28. Davis ID, Brady B, Kefford RF et al (2009) Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 15:2123-2129. doi: 10.1158/1078-0432.CCR-08-2663
29. Petrella TM, Tozer R, Belanger K et al (2012) Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 30:3396-3401. doi: 10.1200/JCO.2011.40.0655
30. Croce M, Corrias MV, Orengo AM, Brizzolara A, Carlini B, Borghi M, Rigo V, Pistoia V, Ferrini S (2010) Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice. Int J Cancer 127:1141-1150. doi: 10.1002/ijc.25140
31. Russell HV, Strother D, Mei Z, Rill D, Popek E, Biagi E, Yvon E, Brenner M, Rousseau R (2008) A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother 31:812-819. doi: 10.1097/CJI.0b013e3181869893
32. Rousseau RF, Haight AE, Hirschmann-Jax C et al (2003) Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotoxin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101:1718-1726
33. Fest S, Huebener N, Bleeke M et al (2009) Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer 125:104-114. doi: 10.1002/ijc.24291
34. Borsellino G, Kleinewietfeld M, Di Mitri D et al (2007) Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110:1225-1232
35. Annacker O, Coombes JL, Malmstrom V et al (2005) Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 202:1051-1061
36. Chesler L, Goldenberg DD, Seales IT et al (2007) Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 67:9435-9442
37. Colombo MP, Piconese S (2007) Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7:880-887
38. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759-767. doi: 10.1002/ijc.25429
39. Frumento G, Piazza T, Di Carlo E, Ferrini S (2006) Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 6:233-237
40. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings M (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212:28-50
41. Terabe M, Berzofsky JA (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101:277-348
42. Heinzel FP, Rerko RM (1999) Cure of progressive murine leishmaniasis: interleukin 4 dominance is abolished by transient CD4(+) T cell depletion and T helper cell type 1-selective cytokine therapy. J Exp Med 189:1895-1906
43. Jing W, Gershan JA, Johnson BD (2009) Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood 113:4449-4457. doi: 10.1182/blood-2008-11- 190827
44. Kalams SA, Walker BD (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188:2199-2204
45. Kim YH, Duvic M, Obitz E et al (2007) Clinical efficacy of zanolimumab (HuMax-CD4), two Phase 2 studies in refractory cutaneous T cell lymphoma. Blood 109:4655-4662
46. D'Amore F, Radford J, Relander T et al (2010) Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 150:565-573. doi: 10.1111/j.1365-2141.2010.08298.x